VELSUI 45 Table 1: Demographic characteristics of the study participants at baseline according to treatment group Laser group (n=30) PFMT group (n=30) All participants (n=60) Age (years) 51.70 ± 8.48 50.00 ± 11.22 50.85 ± 9.90 BMIa 24.98 ± 3.95 23.90 ± 3.79 24.44 ± 3.88 Parity 1.87 ± 0.86 2.03 ± 0.96 1.95 ± 0.91 Menopause 15/30 (50%) 11/30 (36.7%) 26/60 (43.3%) Smoking 4/30 (13.3%) 0/30 (0%) 4/60 (6.7%) Previous hysterectomy 1/30 (3.3%) 2/30 (6.7%) 3/60 (5%) SUI severityb Mild Moderate Severe 15/30 (50%) 15/30 (50%) 0/30 (0%) 12/30 (40%) 18/30 (60%) 0/30 (0%) 27/60 (45%) 33/60 (55%) 0/60 (0%) Concomitant UUIc 8/30 (26.7%) 12/30 (40%) 20/60 (33.3%) aBMI: Body Mass Index. bSUI: Stress Urinary Incontinence; severity as assessed by the Sandvik index. cUUI: Urge Urinary Incontinence; assessed by the UDI-6 questionnaire. Data are mean ± SD or n/N (%) as appropriate. Table 2: Subjective outcomes at baseline and after 4 months. Laser PFMT Mean difference between groups p-value Converted UDI-6 score N=28 N=26 Baseline 70.90 ± 32.25 86.47 ± 30.53 4 months 60.76 ± 32.09 74.94 ± 28.93 Mean difference versus baseline -6.98 (-22.34;8.37) 0.023 Subjective curea 3/28 (10.7%) 2/26 (7.7%) 1.000 PISQ-IR score (sexually active patients) N=24 N=20 Baseline 3.26 ± 0.54 3.38 ± 0.43 4 months 3.47 ± 0.50 3.42 ± 0.54 Mean difference versus baseline 0.21 (0.01;0.41) 0.07 (-0.15;0.230) 0.13 (-0.17;0.44) 0.376 aSubjective cure is defined as answering “No” (0) to the question “Do you experience urine leakage related to physical activity, coughing or sneezing?”. Data are mean ± SD or n/N (%) as appropriate. Change scores were calculated between 4 months follow up and baseline; a positive change score means increase, a negative change score means decrease.
RkJQdWJsaXNoZXIy MTk4NDMw